IRON

+ Watchlist + Portfolio

Disc Medicine, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $80.32
52-Week Range: $40.00 – $99.50
Market Cap: $3.03B
P/E (TTM): —
EPS (TTM): -6.59
Dividend Yield: —

Advanced Metrics

Price/Book: 4.69
PEG Ratio: —
Return on Equity: -39.08%
Return on Assets: -23.96%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 24.14
Debt/Equity: 0.09
Total Debt: $60.86M
Free Cash Flow: $-117.54M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.37B

IRON Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$33.44M	$69.26M	$96.67M	$170.64M
Selling, General & Admin	$14.04M	$21.86M	$33.05M	$65.38M
Operating Expenses	$47.48M	$91.13M	$129.72M	$236.02M
Operating Income	-$47.48M	-$91.13M	-$129.72M	-$236.02M
EBITDA	-$47.39M	-$76.23M	-$108.27M	-$207.94M
Pretax Income	-$46.83M	-$76.33M	-$109.00M	-$211.82M
Income Tax	$0.00	$99.00K	$355.00K	$361.00K
Net Income	-$46.83M	-$76.43M	-$109.36M	-$212.18M
Diluted EPS	-45.05	-3.42	-3.96	-6.01
Diluted Shares	1.04M	22.32M	27.61M	35.30M

IRON Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$194.61M	$360.38M	$192.43M	$91.14M
Current Assets	$198.49M	$365.66M	$493.62M	$803.90M
Total Assets	$200.21M	$368.00M	$496.77M	$806.88M
Current Liabilities	$22.58M	$21.44M	$23.32M	$36.64M
Long-Term Debt	—	—	$28.32M	$29.16M
Total Debt	$1.33M	$2.10M	$30.00M	$31.02M
Total Liabilities	$23.61M	$22.88M	$53.19M	$67.05M
Retained Earnings	-$112.22M	-$188.65M	-$298.00M	-$510.19M
Shareholders' Equity	$176.60M	$345.12M	$443.59M	$739.83M
Working Capital	$175.91M	$344.22M	$470.30M	$767.26M

IRON Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$42.25M	-$73.46M	-$93.93M	-$180.39M
Capital Expenditure	-$151.00K	-$89.00K	-$505.00K	-$933.00K
Free Cash Flow	-$42.40M	-$73.55M	-$94.43M	-$181.33M
Depreciation & Amortisation	$89.00K	$100.00K	$156.00K	$281.00K
Stock-Based Compensation	$2.09M	$5.53M	$16.82M	$34.34M
Investing Cash Flow	-$151.00K	-$89.00K	-$292.33M	-$394.30M
Financing Cash Flow	$148.98M	$239.38M	$218.31M	$473.41M
Net Change in Cash	$106.58M	$165.83M	-$167.94M	-$101.28M

IRON Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$27.76M	$46.32M	$50.33M	$46.22M	$45.90M
Selling, General & Admin	$12.18M	$15.09M	$17.36M	$20.75M	$23.62M
Operating Expenses	$39.95M	$61.41M	$67.70M	$66.97M	$69.52M
Operating Income	-$39.95M	-$61.41M	-$67.70M	-$66.97M	-$69.52M
EBITDA	-$33.05M	-$54.20M	-$61.22M	-$59.47M	-$62.52M
Pretax Income	-$33.97M	-$55.20M	-$62.22M	-$60.44M	-$63.45M
Income Tax	$119.00K	$52.00K	$102.00K	$88.00K	$51.00K
Net Income	-$34.09M	-$55.25M	-$62.32M	-$60.53M	-$63.50M
Diluted EPS	-1.02	-1.58	-1.77	—	-1.65
Diluted Shares	33.32M	35.02M	35.18M	—	38.49M

IRON Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$122.67M	$127.34M	$140.66M	$91.14M	$88.91M
Current Assets	$705.60M	$661.59M	$627.17M	$803.90M	$747.46M
Total Assets	$709.27M	$665.06M	$630.46M	$806.88M	$750.21M
Current Liabilities	$18.74M	$20.61M	$26.74M	$36.64M	$31.14M
Long-Term Debt	$28.53M	$28.74M	$28.95M	$29.16M	$29.36M
Total Debt	$30.64M	$30.92M	$30.98M	$31.02M	$31.06M
Total Liabilities	$48.90M	$50.90M	$57.07M	$67.05M	$61.78M
Retained Earnings	-$332.09M	-$387.33M	-$449.65M	-$510.19M	-$573.69M
Shareholders' Equity	$660.36M	$614.16M	$573.39M	$739.83M	$688.43M
Working Capital	$686.86M	$640.99M	$600.42M	$767.26M	$716.31M

IRON Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$41.38M	-$47.92M	-$47.80M	-$43.30M	-$62.24M
Capital Expenditure	-$851.00K	-$36.00K	-$26.00K	-$20.00K	—
Free Cash Flow	-$42.23M	-$47.95M	-$47.83M	-$43.32M	-$62.24M
Depreciation & Amortisation	$20.00K	$85.00K	$87.00K	$89.00K	$89.00K
Stock-Based Compensation	$6.36M	$8.42M	$9.51M	$10.04M	$11.95M
Investing Cash Flow	-$272.63M	$51.69M	$49.54M	-$222.89M	$58.31M
Financing Cash Flow	$244.25M	$892.00K	$11.59M	$216.68M	$1.70M
Net Change in Cash	-$69.76M	$4.66M	$13.33M	-$49.52M	-$2.23M

Market Snapshot

About

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for patients with serious hematologic diseases. The company's research centers on diseases of red blood cell biology, including anemia and iron metabolism disorders. Disc Medicine's pipeline includes therapies targeting conditions such as myelodysplastic syndromes (MDS), myelofibrosis, and other blood disorders. The company utilizes its understanding of hepcidin biology and iron regulation to develop innovative therapeutic approaches. Their lead programs aim to address significant unmet medical needs in hematology.